Galectin

Galectin-1, a novel promising target for outcome prediction and treatment in SCLC

22 views | Jun 08 2023

This study suggests that Gal-1 may serve as a prognostic biomarker and therapeutic target in small-cell lung cancer based on its correlation with poor overall survival and the significant reduction in tumor size observed with Gal-1 inhibition in a SCLC-PDX model. [Read the Full Post]

Regulation of Expression of Sterol Regulatory Element-binding Protein 1 in Thyroid Cancer Cells

12 views | Dec 12 2022

Tung-Sun Huang et al. thought that lenvatinib and selumetinib decreased SREBP1 expression in the BRAF-mutant cell line BHT-101. [Read the Full Post]

Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease

49 views | Dec 12 2022

Fredrik R Zetterberg et al. found a high affinity (nM) thiodigalactoside GB0139 which was in clinical development (PhIIb) as an inhaled treatment of idiopathic pulmonary fibrosis. [Read the Full Post]